Overview

Neurobiology of Bulimia Nervosa

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone levels. This line of research could lead to the development of pharmacological interventions developed to target specific areas of the brain, brain receptors, or pathways identified to be involved in the mechanism underlying ovarian hormone change and binge eating.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Hormones
Leuprolide
Polyestradiol phosphate
Progesterone